Clinical trial · Interventional
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
A Phase II Study of JS207 (PD-1/VEGF Dual Antibody) in Combination With or Without JS004 or Docetaxel in Advanced Non-small Cell Lung Cancer With Disease Progression During or After the Treatment of Platinum-based Chemotherapy and Immunotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Why stopped (as posted): The research and development strategy was adjusted, so the research was suspended
Summary
Brief summary (as posted)
This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced NSCLC | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| JS207 injection | Drug | — | UNRESOLVED |
| JS207 injection +docetaxel | Drug | — | UNRESOLVED |
| JS207 injection +JS004 injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Arm A
- description
- Patients receive JS207 10mg/kg or other dosage and docetaxel 75mg/m2, q3w.
- interventionNames
- Drug: JS207 injection +docetaxel
- type
- EXPERIMENTAL
- label
- Arm B
- description
- Patients receive JS207 10mg/kg or other dosage and JS004 200mg, q3w.
- interventionNames
- Drug: JS207 injection +JS004 injection
- type
- EXPERIMENTAL
- label
- Arm C
- description
- Patients receive JS207 10mg/kg or other dosage .
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) NSCLC that is not amenable to radical surgery or radical radiochemotherapy, or Metastatic or recurrent NSCLC. 2. Subjects with unresectable locally advanced or metastatic or recurrent NSCLC who have failed first-line treatment with PD-1/PD-L1 inhibitors combined with platinum-based doublet chemotherapy (excluding docetaxel); or who have failed sequential first- and second-line treatment with PD-1/PD-L1 inhibitors followed by platinum-based doublet chemotherapy (excluding docetaxel). 3. Subjects must have at least one measurable lesion according to RECIST v1.1. Exclusion Criteria: 1. Histopathologically or cytopathologically confirmed to have combined neuroendocrine component. 2. Sensitivity mutation of EGFR or ALK fusion. 3. Tumor encircles important blood vessels or has obvious necrosis and air space, and the investigator considers that it may cause hemorrhage risk.
References
Publications (0)
Data not yet available